537 related articles for article (PubMed ID: 11342908)
21. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
22. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
24. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy of testicular cancer: 10-year experience.
Ondrus D; Hornák M; Matoska J; Kausitz J; Belan V; Cársky S
Neoplasma; 1993; 40(4):247-53. PubMed ID: 7505886
[TBL] [Abstract][Full Text] [Related]
26. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer.
Coogan CL; Hejase MJ; Wahle GR; Foster RS; Rowland RG; Bihrle R; Donohue JP
J Urol; 1996 Nov; 156(5):1656-8. PubMed ID: 8863564
[TBL] [Abstract][Full Text] [Related]
27. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
28. Post-chemotherapy resection of nonseminomatous germ cell testicular tumors metastatic to the mediastinum.
Hejase MJ; Donohue JP; Foster RS; Bihrle R; Coogan CL; Rowland RG; Wahle GR
J Urol; 1996 Oct; 156(4):1345-8. PubMed ID: 8808868
[TBL] [Abstract][Full Text] [Related]
29. Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage B1 nonseminomatous germ cell tumor.
Beck SD; Foster RS; Bihrle R; Cheng L; Ulbright TM; Donohue JP
J Urol; 2005 Jul; 174(1):143-5. PubMed ID: 15947600
[TBL] [Abstract][Full Text] [Related]
30. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
Matveev VB; Volkova MI; Cherniev VA; Figurin KM; Mitin AV
Urologiia; 2010; (3):41-7. PubMed ID: 20734877
[TBL] [Abstract][Full Text] [Related]
31. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
[TBL] [Abstract][Full Text] [Related]
32. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
33. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
34. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Urol; 2009 Jun; 181(6):2526-32. PubMed ID: 19371895
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study of retroperitoneal lymph node dissection for patients with advanced germ cell tumors].
Okamura K; Yuba H; Nishimura T; Mizutani K; Takashi M; Gotoh M; Ono Y; Ohshima S
Hinyokika Kiyo; 1999 Feb; 45(2):95-101. PubMed ID: 10212781
[TBL] [Abstract][Full Text] [Related]
37. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
38. Primitive neuroectodermal tumor arising in a testicular teratoma with retroperitoneal metastasis: report of an interesting case with review of literature.
Mohanty SK; Balani JP; Parwani AV
Urology; 2007 Oct; 70(4):812.e7-10. PubMed ID: 17991577
[TBL] [Abstract][Full Text] [Related]
39. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
Sexton WJ; Wood CG; Kim R; Pisters LL
J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
[TBL] [Abstract][Full Text] [Related]
40. Primary pure teratoma of the testis.
Simmonds PD; Lee AH; Theaker JM; Tung K; Smart CJ; Mead GM
J Urol; 1996 Mar; 155(3):939-42. PubMed ID: 8583612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]